Ryan Klein, MD
Internal Medicine · Newport Beach, CANPI 1184620866
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by GSK at 32.6% of the total. Reporting peaked in 2019 at $36,806 and has fallen 90.3% since, to $3,554 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,251 payments — averaging $62.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$26K
- AstraZeneca$16K
- Boehringer Ingelheim$9K
- Sanofi$6K
- Sunovion Pharmaceuticals Inc.$3K
- Genentech USA, Inc.$2K
- plus $15K from 54 others
Across 957 payments — averaging $5148.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.2M
- Boehringer Ingelheim$483K
- GSK$301K
- United Therapeutics Corporation$278K
- Insmed, Inc.$244K
- Astrazeneca UK Limited$226K
- plus $1.2M from 16 others
What the payments were for
- Consulting fees$4,5556%
- Speaking & faculty fees$42,53054%
- Travel & lodging$5,0866%
- Food & beverage$25,95333%
- Education$2750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$23,166
- FASENRA$12,431
- DUPIXENT$4,049
- LONHALA MAGNAIR$3,016
- BREZTRI$1,676
- XOLAIR$1,455
- B Flex$500
- OFEV$470
- Life2000 Ventilation System$450
- AIRSUPRA$272
- TEZSPIRE$219
- FLOWTRIEVER CATHETER, S$123
- CT THROMBECTOMY SYSTEM KIT$123
- FARXIGA$104
How this compares
$78,399 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 224 | $174,022 |
| MounjaroTirzepatide | 115 | $135,547 |
| EliquisApixaban | 190 | $135,282 |
| Breo ElliptaFluticasone/Vilanterol | 124 | $65,143 |
| JanuviaSitagliptin Phosphate | 66 | $61,165 |
| Spiriva RespimatTiotropium Bromide | 71 | $51,167 |
| TrulicityDulaglutide | 36 | $42,012 |
| JanumetSitagliptin Phos/Metformin Hcl | 53 | $34,370 |
| Metformin Er GastricMetformin Hcl | 22 | $26,568 |
| OzempicSemaglutide | 25 | $24,942 |
| RybelsusSemaglutide | 19 | $19,851 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $18,784 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 74 | $18,532 |
| Spiriva HandihalerTiotropium Bromide | 17 | $18,448 |
| Arnuity ElliptaFluticasone Furoate | 36 | $15,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $25,534 | $266,065401 claims |
| Lilly USA, LLCMounjaro, Trulicity | $456 | $177,559151 claims |
| PfizerEliquis, Paxlovid | $722 | $136,711209 claims |
| MerckJanuvia, Janumet, Janumet Xr | $241 | $114,320133 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $9,424 | $60,68982 claims |
| Novo NordiskOzempic, Rybelsus | $219 | $44,79344 claims |
| Johnson & JohnsonXarelto | $442 | $13,16914 claims |
| AstraZenecaSymbicort | $16,206 | $2,87612 claims |
| AbbVieSynthroid | $1,582 | $1,33626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Newport Beach
- Tung NgoNewport Beach$4.9M
- Andrew ChengSouth San Francisco$55.1M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.